US 11,987,851 B2
Reagents and methods for detecting HCV
Arejas Uzgiris, Berkeley, CA (US); Sunil Pandit, Danville, CA (US); and Lance Palmer, Collierville, TN (US)
Assigned to Siemens Healthcare Diagnostics Inc., Tarrytown, NY (US)
Filed by Siemens Healthcare Diagnostics Inc., Tarrytown, NY (US)
Filed on Mar. 17, 2021, as Appl. No. 17/249,896.
Application 17/249,896 is a division of application No. 15/366,147, filed on Dec. 1, 2016, granted, now 10,982,294.
Application 15/366,147 is a division of application No. 14/127,224, granted, now 9,528,163, issued on Dec. 27, 2016, previously published as PCT/US2012/043312, filed on Jun. 20, 2012.
Claims priority of provisional application 61/645,149, filed on May 10, 2012.
Claims priority of provisional application 61/498,870, filed on Jun. 20, 2011.
Prior Publication US 2021/0214810 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/70 (2006.01)
CPC C12Q 1/707 (2013.01) 17 Claims
 
1. A method of performing a polymerase chain reaction (PCR) on an HCV NS3 1a target nucleic acid sequence in a sample comprising:
contacting the sample with a set of outer primers, wherein the set of outer primers comprises one or more forward primers and one or more reverse primers,
wherein the one or more forward primers comprise:
a primer comprising SEQ ID NO: 1 or an active fragment thereof,
a primer comprising SEQ ID NO: 2 or an active fragment thereof,
a primer comprising SEQ ID NO: 3 or an active fragment thereof,
a primer comprising SEQ ID NO: 4 or an active fragment thereof,
a primer comprising SEQ ID NO: 5 or an active fragment thereof, or
a combination thereof; and
wherein the one or more reverse primers comprise:
a primer comprising SEQ ID NO: 6 or an active fragment thereof,
a primer comprising SEQ ID NO: 7 or an active fragment thereof,
a primer comprising SEQ ID NO: 8 or an active fragment thereof,
a primer comprising SEQ ID NO: 9 or an active fragment thereof,
a primer comprising SEQ ID NO: 10 or an active fragment thereof, or
a combination thereof;
wherein an active fragment is 15 or more nucleotides in length; and submitting the resulting mixture to a first PCR.